All In Biotech

Drug Trial Radar · NCT03316599

Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer

Phase 1b Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer

Last checked: Nov 20, 2026Latest source record: Aug 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

26

Actual

Start

Jan 17, 2018

Primary completion

Oct 10, 2020

Study completion Jul 29, 2021

Sponsor

Lead sponsor
Dana-Farber Cancer InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
AVEO Pharmaceuticals, Inc.
First posted
Oct 20, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To identify the maximally tolerated dose of ficlatuzumab when combined with nab-paclitaxel and gemcitabine in patients with previously untreated pancreatic cancer.

Conditions

  • Pancreatic Cancer

Interventions

  • GemcitabineDrug

    Gemcitabine is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.

  • Nab-paclitaxelDrug

    Nab-paclitaxel is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells

  • FiclatuzumabDrug

    It is selective recombinant humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G subclass 1 monoclonal antibody which blocks the MET tyrosine kinase receptor.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Maximum Tolerated Dose of ficlatuzumab when administered in combination with gemcitabine and nab-paclitaxelTime frame: 2 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.